Levorphanol - Relmada Therapeutics

Drug Profile

Levorphanol - Relmada Therapeutics

Alternative Names: LevoCap; LevoCap ER; REL 1015; TQ-1020

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraQuest Biosciences
  • Developer Relmada Therapeutics
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; NMDA receptor antagonists; Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO, Controlled release)
  • 09 Sep 2015 Relmada Therapeutics has patent protection for SECUREL technology and levorphanol in USA
  • 12 May 2015 Relmada received a notice of allowance for the securel abuse deterrent technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top